COMMUNIQUÉS West-GlobeNewswire

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
06/08/2025
–European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track – – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England [...]
American Shared Hospital Services Announces Second Quarter Financial Results Conference Call
06/08/2025
Call Scheduled for August 13th at 1:00 PM ET SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery [...]
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
06/08/2025
– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest [...]
Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025
06/08/2025
Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a [...]
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
06/08/2025
NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5 th Annual [...]
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
06/08/2025
WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring [...]
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
06/08/2025
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in [...]
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies
06/08/2025
Dexmedetomidine demonstrated a significant reduction in stress-induced behaviors, suggesting potential applications of BXCL501 in chronic psychiatric disorders in addition to treatment of acute agitation Leading [...]
Bioventus Reports Second Quarter Financial Results
06/08/2025
Q2 reported revenue of $147.7 million declined 2.4% ; Organic* revenue advanced 6.2% Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period Non-GAAP [...]
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
06/08/2025
– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers [...]
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
06/08/2025
– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in June 2025; top-line [...]
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study
06/08/2025
PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading [...]

Pages